DCAL Q2 FY26 Earnings Call: Strong EBITDA Growth, Margin Expansion

Management guided margin improvementOrder pipeline disclosedCFO laid out a debt-reduction roadmapInvestor Communications View source PDF Explain this filing

DCAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.2%Reaction day

₹246.00

prior close

₹246.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%+3.2% vs market

Pharmaceuticals peers, median of 157sector+0.8%+3.4% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+1.8

15m

+2.1

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.2+0.9+3.2+0.8+3.4

Next day

+0.7+0.8-0.2+0.5+0.2

+0.6+0.7-0.1+0.4+0.3

+2.1+1.3+0.7+0.4+1.6

+1.4+0.5+0.9-0.1+1.6

-1.6+0.4-2.0-0.6-1.1

-1.2-1.5+0.3-1.2-0.1

15d

-3.7-2.4-1.2-1.8-1.9

-11.2-4.4-6.8-2.6-8.7

+5.0-7.2+12.3-5.4+10.4

-15.4-5.0-10.5-5.7-9.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY26 revenue INR 652.6 cr. H1 EBITDA INR 289.5 cr, up 64% YoY with margin at 21.3% versus 13.4% earlier. PAT at INR 88.6 cr versus negative INR 44 cr. Net debt down to CHF 141M from CHF 157M. CDMO EBITDA margin hit 25.3%. Guides FY26 EBITDA margin of 20% and CDMO revenue of INR 3,000 cr for FY27. Plans INR 500 to 700 cr fundraise to retire India debt. French facility breakeven expected next year.

Likely market impact

Strong H1 performance with margin expansion and debt reduction reinforces growth outlook. FY27 targets and 25% ROCE goal over 4 to 5 years signal significant value creation.